MP and CTX ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 1 |
222. Primary nephrotic syndrome
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03466801 (ClinicalTrials.gov) | March 20, 2018 | 13/1/2018 | The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I. | The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I. | Idiopathic Membranous Nephropathy | Drug: Prednisone;Drug: MP and CTX | Wenhu Liu | NULL | Terminated | 18 Years | 80 Years | All | 6 | N/A | China |